Imipramin

Imipramine, the active ingredient in Imipramin, is a tricyclic antidepressant presented as an oral tablet for oral use. It treats major depressive disorder, panic disorder, and nocturnal enuresis in adult patients and, under specialist supervision, in children with enuresis.

GNH USA supplies Imipramin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imipramin is a tricyclic antidepressant that acts on mood‑regulating neurotransmitters and is used for several psychiatric and urological conditions. - Major depressive disorder: alleviates depressive symptoms and improves mood in adult patients. - Panic disorder: reduces the frequency and severity of panic attacks. - Nocturnal enuresis: decreases nighttime urinary episodes in children.

Imipramin may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dry mouth: reduced salivary flow causing discomfort. - Constipation: slowed gastrointestinal motility. - Drowsiness: increased sedation, especially at treatment initiation. - Weight gain: increased appetite and caloric intake. - Blurred vision: transient visual disturbances. - Urinary retention: difficulty emptying the bladder.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, particularly in patients with pre‑existing heart disease. - Seizures: heightened risk in susceptible individuals. - Severe hypotension: sudden drop in blood pressure. - Agranulocytosis: marked reduction in white blood cells. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Liver toxicity: abnormal liver function tests or hepatitis.

Before initiating Imipramin therapy, several safety considerations should be observed. - Cardiac assessment: obtain baseline ECG in patients with known heart disease. - Dose titration: start at a low dose and increase gradually under medical supervision. - Drug interactions: review all concomitant medications for potential interactions. - Suicidality monitoring: closely observe for worsening depression or emergent suicidal thoughts. - Pregnancy and lactation: use only if the expected benefit outweighs potential risks. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Imipramin can interact with a variety of medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertensive crisis. - Selective serotonin reuptake inhibitors (SSRIs): increased serotonin syndrome risk. - Other tricyclic antidepressants: additive cardiotoxic effects. - Certain antihistamines: heightened anticholinergic burden. - Linezolid: potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): may raise imipramine plasma levels. - Anticholinergic drugs: exacerbate dry mouth, constipation, urinary retention. - Alcohol: enhances central nervous system depression. - CNS depressants (e.g., benzodiazepines): increased sedation. - Diuretics: may potentiate orthostatic hypotension.